Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 1/20 | 0.41 |
| ▸ | GRIN2B | Q13224 | 5/20 | 0.40 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | MAOB | P27338 | 1/20 | 0.35 |
| ▸ | PLAU | P00749 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.32 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4289135 | 0.82 | DRD2 (0.37) | — | |
| SCHEMBL5591941 | 0.82 | HTR2C (0.38) | KDM1A | |
| SCHEMBL8630503 | 0.80 | PRCP (0.37) | CYP11B2GRIN2BSIGMAR1KDM1AMAOA | |
| SCHEMBL10596489 | 0.80 | ESR1 (0.40) | GRIN2B | |
| SCHEMBL5715615 | 0.75 | POLB (0.38) | SIGMAR1GAAALDH1A1 | |
| SCHEMBL4282799 | 0.75 | HSD11B1 (0.36) | KDM1A | |
| SCHEMBL7610196 | 0.74 | SLC6A2 (0.36) | SIGMAR1ALDH1A1 | |
| SCHEMBL1494065 | 0.74 | DDB1 (0.38) | GRIN2BALDH1A1 | |
| SCHEMBL4931080 | 0.73 | CYP1A2 (0.40) | CYP11B2KDM1AGAAALDH1A1MTNR1A | |
| SCHEMBL4283465 | 0.72 | MEN1 (0.45) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7932261-B2 | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | claimed |
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | claimed |
| US-9182669-B2 | Copolymer with acid-labile group, photoresist composition, coated substrate, and method of forming an electronic device | ROHM AND HAAS ELECTRONIC MATERIALS LLC (US) | 2015-11-10 | — | — | US | disclosed |
| US-20150177614-A1 | COPOLYMER WITH ACID-LABILE GROUP, PHOTORESIST COMPOSITION, COATED SUBSTRATE, AND METHOD OF FORMING AN ELECTRONIC DEVICE | U.S. BANK TRUST COMPANY, NATIONAL ASSOCIATION, AS NOTES COLLATERAL AGENT | 2015-06-25 | — | — | US | disclosed |
| WO-2015034778-A1 | METHODS OF TREATING ERECTILE DYSFUNCTION | BIOMIMETIX J.V., LLC (US) | 2015-03-12 | — | — | WO | disclosed |
| US-7932261-B2 | Macrocycle derivatives useful as inhibitors of β-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-26 | — | — | US | disclosed |
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2007-10-04 | — | — | US | disclosed |
| WO-2007092839-A2 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-08-16 | — | — | WO | disclosed |
| US-20060211724-A1 | Hiv integrase inhibitors | VERSCHUEREN GASTON W | 2006-09-21 | — | — | US | disclosed |
| EP-1625130-A2 | HIV INTEGRASE INHIBITORS | Tibotec Pharmaceuticals Ltd. (IE) | 2006-02-15 | — | — | EP | disclosed |
| WO-2004096807-A2 | HIV INTEGRASE INHIBITORS | TIBOTEC PHARMACEUTICALS LTD. (IE) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232630-A1 | MACROCYCLE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | CYP11B2 2301/4885GRIN2B 137/4885SIGMAR1 4783/4885 |
| US-20060211724-A1 | Hiv integrase inhibitors | SULT1A1, SULT2A1, SULT1E1 | CYP11B2 282/4885GRIN2B 1249/4885SIGMAR1 101/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.